Clinical Trial Update: A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A multicenter, open-label, non-randomized Phase I/IIa trial evaluating INR102 Injection in patients with prostate cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• INR102 Injection

Snippet

Sponsor: Yunhe Pharmaceutical (Tianjin) Co., Ltd | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING